9013 RESULTS
COMMENT With Peter, the field loses a pioneer and a charismatic and inspiring leader. Personally, it feels like losing a friend. His work was fundamental to the acetylcholine hypothesis and the first drugs for Alzheimer’s disease. In later years, he focused on ...
COMMENT Peter was clearly one of the greatest investigators in the pantheon of Alzheimer’s researchers. I knew him as a dear friend and valued mentor since the '80s. I always valued his great balance of scientific objectivity and empathy, especially for ...
COMMENT “I’m not a tauist, I’m a Roman Catholic.” This quote by Peter encapsulates some of the endearing qualities I have appreciated from knowing him over four decades. His quiet sense of humor, his gentle statesmanship, his ability to defend eloquently (and in ...
COMMENT I met Peter at the beginning of my career, when I was first starting the Ph.D. portion of my M.D., Ph.D. program. Peter was such an exciting person to work with. He was passionate about research and discovery. He came into the field with major impact by ...
COMMENT I was deeply saddened to hear that Peter had passed recently. I had deep respect for Peter as a scientist and a colleague. Publically, Peter kept faith as a “tauist” and championed its role in AD and related disorders. Especially in the early 1990s, this ...
COMMENT Peter Davies, who was only 72 years old when he died on August 26, made important contributions to two different areas of research into Alzheimer’s disease. In the 1970s, he was a major proponent of the cholinergic hypothesis of Alzheimer’s disease ...
COMMENT This is a very elegant and profound paper that introduces a new therapeutic concept to the field of neurological diseases. Based on previously known molecular neurobiological and structural information, the authors have successfully generated an ...
COMMENT The involvement of the immune system in Alzheimer’s disease (AD) is well-established. Immune activity is thought to play several roles in the progression of AD pathology, which may be both beneficial and detrimental, notably: neuroinflammation and ...
COMMENT In the more than 20 years of study of γ-secretase and its role in AD, many high-profile reports have touted the discovery of modulatory proteins with potential as therapeutic targets, only leading to a disappointing inability to validate and extend those ...
COMMENT This work on a γ-secretase-modulating protein IFITM3 published by Yue-Ming Li's group is a sequel to his Nature article on presenilin-labeling active site γ-secretase inhibitors published in 2000. The γ-secretase complex and its modulators have been ...
COMMENT This is really nice work from Drs. Hur, Frost, and a team of collaborators led by Yue-Ming Li. Yue-Ming belongs to a small group of researchers who did pioneering work on the γ-secretase complex (or better yet, complexes, each having very different ...
COMMENT I thank Dr. Nelson for responding. Often we do not hear back from the senior authors on these posts, so the effort to continue this debate is encouraging. I will only comment on the issue of prevalence. Much of the data on this has come from the ...
COMMENT The comments above raise important issues related to an understudied but common disease(s). I first offer individual responses, then some overarching points. I agree with Dr. Boxer that therapeutics for one subtype of TDP-43 proteinopathy may work for ...
COMMENT Please excuse my tardiness in posting, but I just noticed a comment made by Michael Wolfe, concerning experimental conditions in our paper, Netzer et al. Dr. Wolfe's statement that N2a cells expressing a stable transfection of APP 695 were compared ...
COMMENT Few scientists in the Alzheimer's field would disagree that we need an animal model that more faithfully manifests the disease as it occurs in humans. Genetically modified mice have been a boon to studies of cellular and molecular mechanisms, but ...
